Oppenheimer Maintains Outperform on Immunovant, Raises Price Target to $53
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Leland Gershell has maintained an Outperform rating on Immunovant (NASDAQ:IMVT) and raised the price target from $47 to $53.
October 09, 2024 | 2:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer has reaffirmed its Outperform rating on Immunovant and increased the price target to $53, indicating confidence in the company's future performance.
The increase in price target from $47 to $53 by Oppenheimer suggests a positive outlook on Immunovant's future performance. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100